Effectiveness of Mindfulness-Based Cognitive Therapy on Depressive Symptoms, Brain Potential, and Neuroimmunoinflammatory Factors in Depressed Patients.
Jiancheng Qiu, Yifei Gong, Xiucui Zhang, Weibing Mao
Clinical neuropharmacology DOI: 10.1097/WNF.0000000000000601
Summary
Mindfulness-based cognitive therapy (MBCT) significantly enhances treatment for depression. In a study with 64 patients, those receiving MBCT alongside conventional therapy showed greater improvements in depressive symptoms, with Hamilton Depression Rating Scale scores decreasing more notably compared to the control group. Additionally, inflammatory markers like tumor necrosis factor α and interleukin-6 dropped significantly, while quality of life scores rose. Notably, the MBCT group experienced shorter latency and longer amplitude in brain responses, suggesting enhanced cognitive function. This approach merits broader clinical application.
Abstract
This study was aimed to investigate the effectiveness of mindfulness-based cognitive therapy (MBCT) on depressive symptoms, brain potential, and neuroimmunoinflammatory factors in patients with depression. Sixty-four eligible patients according to the inclusion criteria were randomly divided into the control group and the observation group, with 32 patients in each group. The control group received conventional therapy, while the observation group received MBCT on top of conventional therapy. The depressive symptoms, brain potential, and neuroimmunoinflammatory factors were measured in the two groups. After treatment, the Hamilton Depression Rating Scale score, tumor necrosis factor α, and interleukin-6 levels were decreased, while the World Health Organization Quality of Life Scale score, total number of response execution score, and 5-hydroxy tryptamine level were increased in both groups. Moreover, the Hamilton Depression Rating Scale score, tumor necrosis factor α, and interleukin-6 levels were decreased more significantly, while the World Health Organization Quality of Life Scale score, total number of response execution score, and 5-hydroxy tryptamine level were increased more significantly in the observation group compare to the control group ( P < 0.01). In addition, the latency in the observation group was shorter and the amplitude was longer than those in the control group ( P < 0.01). Compared with conventional therapy, the use of MBCT combined with conventional therapy can effectively reduce depressive symptoms, suppresses inflammatory responses, and optimize attention and response to target stimulation and is worthy of wide clinical implementation.